Deals In Depth: June/July 2012
Walgreen took a 45% stake in Alliance Boots for $6.6 billion. BMS boosted its diabetes portfolio by paying $6.8 billion for Amylin, while German device manufacturer BSN Medical was bought out by EQT for $2.2 billion. Biopharma financing totaled $713 million and $1.3 billion in June and July, respectively. Device fundraising decreased, going from $352 million in June to $126 million the following month.
You may also be interested in...
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.